All members have the option of attending our various HTC-centric events which include:
Date: Wednesday, September 23rd, 2026 Time: 1:00pm - 2:00pm ET WEBINAR TOPIC: Preapproval Information Exchange: Denecimig for the treatment of hemophilia A OBJECTIVES: Denecimig is a novel FVIIIa mimetic agent currently under investigation for the treatment of hemophilia A (congenital FVIII deficiency) with or without FVIII inhibitors. Denecimig has not been approved for any indication Read the full article...
Date: Thursday, September 24th, 2026 Time: 1:00pm - 2:00pm ET WEBINAR TOPIC: Treatments on the Horizon: Research into the Management of Hemophlia A and von Willebrand Disease OBJECTIVES: Provide an update on Genentech pipeline and treatments under investigation for rare blood disorders Review investigational agents and enrolling trials for hemophilia A, highlighting NTX007 and SPK-8011QQ Read the full article...
Date: September 27 - 29, 2026 Location: Washington, DC Please note: this button will redirect you to Cvent, the Alliance's NEW management registration platform. Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
Date: October 9 - 11 (Boston, MA) Click here for info.
